Drug Profile

Tranilast/allopurinol - Nuon Therapeutics

Alternative Names: NU-1618

Latest Information Update: 12 Aug 2015

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nuon Therapeutics
Class Anthranilic acids; Antigouts; Antirheumatics; Purines; Small molecules; Uricosurics
Mechanism of Action Immunomodulators; SLC2A9 protein inhibitors; Xanthine oxidase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Gout; Hyperuricaemia

Most Recent Events

05 Jan 2011 Nuon Therapeutics completes the phase II TAnGO trial in Gout in USA (NCT01109121)
23 Jun 2010 Efficacy and adverse events data from clinical trials in Hyperuricaemia released by Nuon Therapeutics
23 Jun 2010 Pharmacodynamics data from a preclinical trial in Gout released by Nuon Therapeutics

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com